Exelixis, Inc. EXEL

FDA extended the NDA review for Exelixis' zanzalintinib in combination with Roche's Tecentriq for metastatic colorectal cancer from Dec 3, 2026 to Mar 3, 2027 after a major amendment and new safety/efficacy data. STELLAR-303 showed a non-statistically significant overall survival trend in non-liver metastases, despite a prior OS signal in the ITT population. Zanzalintinib is a key near-term catalyst as Exelixis pursues broader combos, including Merck's Keytruda QLEX in STELLAR-316 for resected CRC and the LITESPARK-034 RCC trial. EXEL also operates STELLAR-201 in recurrent meningioma. Cabometyx remains the lead product; label expansions for pNET and epNET occurred in 2025. The delay could slow EXEL's growth beyond Cabometyx, though year-to-date performance reflects investor optimism. Delaying the key near-term catalyst zanzalintinib's NDA decision can materially affect EXEL's growth trajectory and investor sentiment.

FDA extends review of Exelixis's zanzalintinib plus atezolizumab for metastatic colorectal cancer after Exelixis filed a major amendment with updated safety and efficacy data. The extension lengthens the decision timeline but covers only part of what matters today: the ongoing push to diversify beyond cabozantinib. Exelixis notes the delay tests the durability of its strategy while continuing to push a growing late-stage pipeline, including the pivotal STELLAR-303 trial in colorectal cancer as a potential catalyst for approvals and label expansions. Management positions zanzalintinib as a key second pillar to the cabozantinib franchise, amid a competitive field with Roche and Merck. The company, with a market cap around $14.5 billion, faces ongoing pressures from patent cliffs and pipeline uncertainty, but investors can view the regulatory update as a stress test rather than a derailment of its longer-term growth plan. Near-term catalysts are delayed; long-term diversification through zanzalintinib remains a potential driver, balancing impact.

Exelixis pursues oncology deals and prepares zanzalintinib launch while cabozantinib sales exceed $3B. Oncology deals, zanzalintinib launch prep and cabozantinib exceeding $3B in sales signal major strategic and revenue shifts for Exelixis.

Exelixis (EXEL) receives three-month extension on Zanzalintinib review, raising doubts whether data supports approval. Three-month Zanzalintinib review delay introduces approval uncertainty that may shift timelines and sentiment.

Exelixis prepares for Zanza launch while CABOMETYX growth encounters hurdles from NET ramp. Zanza launch plans combined with CABOMETYX growth obstacles signal major shifts in product pipeline and revenue trajectory.

Exelixis targets CABOMETYX growth and Zanzalintinib catalysts across cancer franchises. CABOMETYX expansion and Zanzalintinib catalysts signal major strategic progress in oncology pipelines.

EXEL stock fell after FDA extended review of its cancer drug by three months, with William Blair forecasting additional near-term price swings. Three-month FDA review extension delays cancer drug approval timeline and triggers stock decline plus near-term volatility.

Exelixis shares fell after the company announced an unexpected delay in its cancer treatment program, triggering a bearish move for the IBD 50 stock. Unexpected cancer program delay disrupts Exelixis core drug development timeline and damages near-term investor sentiment.

Exelixis shares fell 3.5% after FDA extended Zanzalintinib review by three months. Three-month FDA delay on Zanzalintinib pushes back potential approval and revenue timelines.

Exelixis posted an earnings shortfall yet its stock broke out to new highs afterward. Earnings shortfall offset by immediate stock breakout points to limited net effect on trajectory.

Exelixis shares hit new highs as investors watch for key upcoming FDA regulatory decisions on its cancer drugs. Pending FDA decisions represent major regulatory catalysts that can drive substantial shifts in company trajectory and investor sentiment.

Exelixis reports strong sales and earnings that drive its shares higher. Strong sales and earnings improve financial performance and lift stock price.

Exelixis (EXEL) held its Q2 2026 earnings call, presenting financial results, operational updates, and forward-looking guidance to investors. Earnings call disclosures deliver core financial metrics and guidance that directly shape near-term stock valuation and investor positioning.

Exelixis cuts 2026 revenue outlook and pivots investments to oncology, triggering a 6.7% stock decline. Revenue outlook cut combined with core oncology investment shift signals major changes to financial trajectory and investor sentiment.

Exelixis beat Q2 earnings estimates but missed sales targets and lowered its 2026 guidance. Q2 sales miss combined with lowered 2026 guidance points to moderate pressure on financial performance and sentiment.

Exelixis Inc posted Q2 2026 results showing strong cabozantinib sales growth that offsets NET segment weakness. Cabozantinib revenue expansion directly supports near-term financial results and investor views on core product performance.

Exelixis reported Q2 financial results and operational updates during its earnings call, covering revenue, pipeline progress, and guidance. Q2 earnings updates deliver financial metrics and outlook that can shift near-term sentiment without guaranteeing major strategic shifts.

Exelixis (EXEL) beat Q2 earnings estimates. Beating quarterly earnings estimates often lifts near-term stock sentiment and valuation for Exelixis.

Exelixis shares fell sharply after its earnings release, despite the stock's top ranking in the IBD 50 list. Earnings release triggered immediate stock price drop, signaling short-term pressure on financial performance outlook.

Exelixis, Inc. reported second quarter 2026 financial results and issued a corporate update. Quarterly earnings releases and corporate updates typically move near-term stock sentiment and valuation for the company.

Exelixis (EXEL) earnings are projected to grow, raising the question of whether investors should buy the stock. Expected earnings growth at Exelixis may moderately influence near-term stock performance and sentiment without fundamentally altering long-term trajectory.

UBS states Exelixis faces balanced risk-reward ahead of key catalysts. UBS analyst note on balanced risk-reward before catalysts may moderately influence EXEL investor sentiment.

Truist’s new analyst shares views on Exelixis (EXEL) and its next-generation cancer drug. Analyst commentary on a key pipeline asset can shift near-term investor sentiment for Exelixis.

Exelixis shares decline after colorectal cancer study data release on Zanzalintinib. Negative colorectal cancer trial data on Zanzalintinib harms Exelixis development outlook and stock performance.

Exelixis provides update on Phase 3 STELLAR-303 trial of zanzalintinib plus immune checkpoint inhibitor in metastatic colorectal cancer. Phase 3 colorectal cancer trial update for pipeline candidate can shift development outlook and investor views on future revenue.

Exelixis wins CABINET trial, expanding CABOMETYX indications and triggering valuation reassessment. CABINET success materially widens CABOMETYX addressable market and shifts Exelixis valuation trajectory.

Exelixis stock reaches new highs driven by rising sales and increased institutional inflows. Growing sales support revenue expansion while institutional inflows lift near-term investor sentiment without altering long-term trajectory.

Exelixis announces subgroup analysis results from phase 3 CABINET trial evaluating CABOMETYX in non-functional and functional neuroendocrine tumors at ASCO 2026. Phase 3 data for core drug CABOMETYX in additional tumor types can drive major revenue growth and valuation shifts.

Exelixis launches new colorectal cancer trials to expand beyond CABOMETYX, drawing investor reactions on growth prospects. New colorectal cancer trials mark major strategic expansion beyond CABOMETYX with potential to alter company trajectory.

Exelixis focuses on CABO growth while awaiting Zanzalintinib clinical readouts and potential colorectal cancer launch. Zanzalintinib readouts and CRC launch represent major clinical and commercial catalysts for Exelixis.